Breast Cancer Genome Guided Therapy Study (BEAUTY)
This study is currently recruiting participants.
Verified August 2013 by Mayo Clinic
Information provided by (Responsible Party):
Matthew P. Goetz, M.D., Mayo Clinic
First received: December 20, 2013
Last updated: NA
Last verified: August 2013
History: No changes posted
The purpose of this research study is to better understand the reasons why or why not breast cancers are destroyed by standard chemotherapy. This information will be used to develop new and better cancer therapies.
||Observational Model: Case-Only
Time Perspective: Prospective
||Breast Cancer Genome Guided Therapy Study (BEAUTY)
Primary Outcome Measures:
- DNA from the germline and breast tumor for the identification of novel somatic changes within gene and gene pathways. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
To obtain DNA from the germline and breast tumor for the identification of novel somatic changes within gene and gene pathways that are potentially "druggable" in men or women with breast cancer undergoing a standard neoadjuvant paclitaxel (with or without trastuzumab), followed by a standard anthracycline containing regimen (e.g. doxorubicin and cyclophosphamide) for breast cancer.
- Frequency of known tumor mutations for which current drug therapies already exist. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
To determine the frequency of known tumor mutations for which current drug therapies already exist (e.g. BRAF, C-KIT, EGFR mutation, KRAS, PTEN, PI3K).
- Breast cancer tissue to develop tumor xenograft cell lines for mechanistic and functional studies. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
Using breast cancer tissue obtained prior to chemotherapy in all patients and following the completion of chemotherapy (in patients with residual tumors > 2 cm or residual nodal disease), to develop tumor xenograft cell lines for mechanistic and functional studies to determine whether mutations identified are associated with the malignant phenotype and response to associated drugs which target the gene and/or pathways.
- Somatic alterations identified are associated with pathologic complete response to therapy. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
To determine whether somatic alterations identified above are associated with pathologic complete response to therapy.
Biospecimen Retention: Samples With DNA
Secondary Outcome Measures:
Breast cancer tissue and blood specimens
| Estimated Enrollment:
| Study Start Date:
| Estimated Primary Completion Date:
||December 2014 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Age ≥18 years.
- Histological confirmation of invasive breast cancer.
Confirmation of breast cancer lesion ≥ 1.5 cm in size by any clinical (physical examination measurement) or radiographic criteria (mammogram, ultrasound or MRI) in the ipsilateral breast.
- Note: Benign breast disease, LCIS or DCIS in the contralateral breast is allowed. Contralateral invasive breast cancer is allowed if disease is of clinically lower stage and the higher stage lesion will be the study lesion for all biopsies and tissue samples.
- Note: Disease in axilla only is not eligible.
- Note: Patients that have a contraindication or inability to have an MRI may still be enrolled on study and not participate in the MRI at any of the study specific time points.
- Note: For patients with bilateral disease the higher clinical stage disease will be the study lesion that will undergo study biopsies and tissue samples from surgery and the contralateral lesion will NOT undergo research biopsies and tissue samples.
Men or women who are to begin neoadjuvant chemotherapy for treatment of Stage I-III Her 2 negative breast cancer with paclitaxel followed by either the combination of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) or the combination of doxorubicin and cyclophosphamide (AC). OR Men or women who are to begin neoadjuvant chemotherapy for treatment of Stage I-III Her 2 positive breast cancer with paclitaxel followed by either the combination of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) or the combination of doxorubicin and cyclophosphamide (AC). MC1137 Trastuzumab will be given concurrently with the taxane portion and can be given concurrently with FEC (but not AC) at the discretion of the medical oncologist.
- Note: Her2 positive disease is defined to be: HER2 score of 3+ by IHC or HER2 gene amplification by FISH.
- Provide informed written consent.
- Willing to return to Mayo Clinic in Rochester, MN, Mayo Clinic in Arizona, or Mayo Clinic in Florida for imaging correlative, surgery, and follow-up.
- Willing to provide blood samples for correlative research purposes.
- Willing to provide tissue samples for correlative research purposes.
- ECOG Performance Status ≤ 2.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02022202
|Contact: Mayo Clinic Clinical Trials Referral Office
|Mayo Clinic campus in Arizona
|Scottsdale, Arizona, United States, 85259 |
|Contact: Mayo Clinic Clinical Trials Referral Office 507-538-7623 |
|Principal Investigator: Donald W. Northfelt, M.D. |
|Rochester, Minnesota, United States, 55905 |
|Contact: Mayo Clinic Clinical Trials Referral Office, 507-538-7623 |
|Principal Investigator: Matthew P. Goetz, M.D. |
||Matthew P. Goetz, M.D.
||Donald W. Northfelt, M.D.
||Mayo Clinic campus in Arizona
||Judy C. Boughey, M.D.
No publications provided
||Matthew P. Goetz, M.D., Study Chair, Mayo Clinic
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 20, 2013
||December 20, 2013
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 17, 2014
Neoplasms by Site